FiscalNote to Participate at the Oppenheimer 28th Annual Technology, Internet & Communications Conference
FiscalNote executives will participate and host one-on-one meetings on Monday, August 11th. To receive additional information, request an invitation, or schedule a one-on-one meeting with management, please contact your Oppenheimer Financial Professional at opcoconferences@opco.com or FiscalNote's Investor Relations team at IR@fiscalnote.com.
For further investor information, please visit the Company's Investor Relations website.
About FiscalNote
FiscalNote (NYSE: NOTE) is the leading SaaS provider of policy and regulatory intelligence. By uniquely combining proprietary AI technology, comprehensive data, and decades of trusted analysis, FiscalNote helps customers efficiently manage political and business risk. Since 2013, FiscalNote has pioneered solutions that deliver critical insights, enabling effective decision making and giving organizations the competitive edge they need. Home to PolicyNote, CQ, Roll Call, VoterVoice, and many other industry-leading products and brands, FiscalNote serves thousands of customers worldwide with global offices in North America, Europe, and Asia. To learn more about FiscalNote and its suite of solutions, visit FiscalNote.com and follow @FiscalNote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Viatris Earnings Call: Growth Amid Challenges
Viatris, Inc. ((VTRS)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Viatris, Inc. painted a picture of mixed sentiment, highlighting both achievements and challenges. The company showcased strong pipeline progress and international growth, particularly in China, while grappling with operational impacts from the Indore facility and declines in the North American and Japanese markets. Despite these hurdles, Viatris remains committed to shareholder returns and has several promising product launches on the horizon, indicating potential for future growth. Strong Pipeline Progress Viatris reported significant advancements in its pipeline, with five out of six anticipated Phase III readouts showing positive results. This includes two ophthalmology programs and a fast-acting formulation of meloxicam, which targets the lucrative $80 billion U.S. acute pain market. These developments underscore the company's focus on innovation and its potential to capture significant market share. Operational Revenue Growth The company achieved a 3% divestiture-adjusted operational revenue growth, largely driven by robust performance in Europe and Greater China. This growth reflects Viatris' strategic efforts to strengthen its presence in key international markets, despite facing challenges in other regions. Shareholder Returns Viatris demonstrated its commitment to shareholder value by returning over $630 million to shareholders, including $350 million in share repurchases this year. This move highlights the company's focus on rewarding its investors and maintaining confidence in its financial health. Positive Developments in China Greater China emerged as a bright spot for Viatris, with net sales growing by 9%, surpassing expectations. This growth was fueled by strong demand and proactive patient choice, showcasing the region's importance to the company's overall strategy. New Product Launches Expected Looking ahead, Viatris anticipates multiple product launches in 2026, including EFFEXOR for generalized anxiety disorder in Japan, XULANE low dose for contraception, and several ophthalmology products. These launches are expected to bolster the company's product portfolio and drive future revenue growth. Indore Facility Impact The Indore facility faced issues that resulted in a negative impact of approximately $160 million, affecting Viatris' operational revenue growth. This setback highlights the operational challenges the company must address to sustain its growth trajectory. Decline in North American Business Viatris' North American business experienced an 11% decline, attributed to the Indore facility impact and increased competition. However, this was partially offset by revenues from new products, indicating some resilience in the market. Japan Sales Decline Sales in Japan decreased by approximately 11%, driven by government price regulations and changes in reimbursement policies. This decline underscores the regulatory challenges Viatris faces in maintaining its market position in Japan. Challenges in Generic Product Approvals The company is experiencing delays in the anticipated timing of approvals and launches of certain generic products, which could negatively impact new product revenues. This challenge highlights the complexities of navigating the generic pharmaceutical landscape. MR-139 Ophthalmology Program Challenges The Phase III study of MR-139 for blepharitis did not meet its primary endpoint, necessitating further work to determine the next steps. This setback indicates the hurdles in developing successful treatments in the ophthalmology sector. Forward-Looking Guidance In its Q2 2025 earnings call, Viatris reaffirmed its financial guidance for 2025, expecting to be in the top half of the range on revenue and adjusted EPS. The company emphasized its strategic initiatives, including advancing its pipeline and conducting a comprehensive enterprise-wide strategic review to position itself for sustainable future growth. Despite potential impacts from U.S. tariffs, Viatris anticipates no material effect on its 2025 financials. In summary, Viatris, Inc.'s earnings call highlighted a blend of strong international growth and pipeline progress, countered by operational and market challenges. The company's commitment to shareholder returns and strategic product launches offer a promising outlook, despite the hurdles it faces in North America and Japan. Investors will be keenly watching how Viatris navigates these challenges and capitalizes on its growth opportunities. Disclaimer & Disclosure Report an Issue
Globe and Mail
2 hours ago
- Globe and Mail
Why Blue Bird Stock Soared More Than 27% Higher This Week
Key Points The veteran bus maker delivered a quarter for the ages. It notched new all-time highs in key fundamentals. 10 stocks we like better than Blue Bird › A beat-and-raise fiscal third quarter was the fuel driving Blue Bird (NASDAQ: BLBD) stock forward this week. Thanks mostly to this the company's shares motored over 27% higher during the period, according to data compiled by S&P Global Market Intelligence. Blue's success with yellow That three-month period saw Blue Bird, a longtime manufacturer of school buses, hit new highs for both quarterly revenue and profitability. The former line item zoomed 19% higher to $398 million, while non-GAAP (adjusted) net income improved by more than 26% to $38.7 million ($1.19 per share). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Analysts were expecting the quarter to be profitable, but not this profitable. As a group they were modeling only $1 per share for adjusted net income. They also underestimated revenue, as they predicted less than $378 million. Although it's identified -- if at all -- with the traditional gas-guzzling yellow school buses, Blue Bird has been busily upgrading its signature product over the years. It has pushed assertively into the alternative-fuel space, embracing greener solutions such as electric vehicle (EV) technology. In its earnings release, Blue Bird referred to "expanding its leadership" in such alt-fuel offerings. It also mentioned that it was able to successfully side-step many of the tariffs recently imposed by the Trump administration, among other results-boosting factors. A lift in guidance With that solid quarter at its back, Blue Bird felt confident enough to raise its full-year-2025 guidance. The company now expects to earn roughly $1.45 billion in revenue and post an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) figure of $205 million to $215 million. It did not provide a net income estimate. Should you invest $1,000 in Blue Bird right now? Before you buy stock in Blue Bird, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Blue Bird wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
CBC
3 hours ago
- CBC
U.S. increases softwood lumber fees on Canada to 35.19%
The U.S. Department of Commerce increased countervailing duties on Canadian softwood lumber on Friday, bringing the total to 35.19 per cent.
